Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Businessweek Archives

Table: A Windfall In The Making


News: Analysis & Commentary: DRUGS

TABLE: A Windfall in the Making

Pharmaceutical makers are seeking an average of 12 months' extra protection

from generic competitors for more than 100 drugs

DRUG MONTHS POTENTIAL EXTRA REVENUES

COMPANY/ OF ADDED BECAUSE OF LACK

USE PROTECTION OF GENERIC ALTERNATIVE

MILLIONS OF DOLLARS

ZANTAC 19 $1,000

Glaxo/ulcers

MEVACOR 19 $448

Merck/

cholesterol-lowering

DIFLUCAN 20 $410

Pfizer/

antifungal agent

PRILOSEC 17 $586

Merck/ulcers

CAPOTEN 6 $101

Bristol-Myers

Squibb/hypertension

DATA: PRIME INSTITUTE, UNIVERSITY OF MINNESOTA


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus